Gilead Struggles to Recruit Patients for Coronavirus Drug Trial in China

On February 5, 2020, it was reported that clinical trials of Gilead Sciences’ remdesivir had launched in Wuhan, China. The experimental antiviral is to be evaluated as a treatment for 2019-nCoV, or what is now being called Covid-19.

But there are now reports that the company and health authorities in China are having difficulties recruiting eligible patients.